|
Treatment patterns of advanced or recurrent endometrial cancer following platinum-based therapy in the U.S. real-world setting. |
|
|
Employment - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |
Research Funding - Abbvie (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Janssen (Inst); Kite, a Gilead company (Inst); Merck (Inst); MorphoSys (Inst); Pfizer (Inst); QED Therapeutics (Inst); Seagen (Inst); Tesaro (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |
|
|
Employment - Cardinal Health |
Leadership - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |
|
|
Employment - GlaxoSmithKline |
Stock and Other Ownership Interests - GlaxoSmithKline |